BullishAgent BullishAgent Filings Economic Earnings Ratings IPOs Insiders Institutional ETFs Funds Screener
Sign in Register

NVAX

Novavax, Inc. NASDAQ Listed Dec 5, 1995
Healthcare ·Biotechnology ·US · novavax.com
$9.24
Mkt Cap $1.5B
52w Low $5.80 55.8% of range 52w High $11.97
50d MA $9.04 200d MA $8.22
P/E (TTM) 3.0x
EV/EBITDA 2.2x
P/B
Debt/Equity -1.9x
ROE -344.6%
P/FCF -4.4x
RSI (14)
ATR (14)
Beta 2.65
50d MA $9.04
200d MA $8.22
Avg Volume 4.1M
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
SIC Code
2836
CIK (SEC)
Phone
240 268 2000
21 Firstfield Road · Gaithersburg, MD 20878 · US
Data updated apr 26, 2026 4:13pm · Source: massive.com